Table 1.

Summary of description of study population by glaucoma status

Patient characteristics	n	Glaucoma (n=46)	No glaucoma (n=564)	Overall (n=610)
Baseline
Drug (Avastin)	610	23 (50.0%)	273 (48.4%)	296 (48.5%)
Age (years)	610	80.0 (7.1)	77.5 (7.4)	77.7 (7.4)
50–69		2 (4.3%)	90 (16.0%)	92 (15.1%)
70–74		13 (28.3%)	97 (17.2%)	110 (18.0%)
75–79		8 (17.4%)	151 (26.8%)	159 (26.1%)
80–84		7 (15.2%)	132 (23.4%)	139 (22.8%)
85+		16 (34.8%)	94 (16.7%)	110 (18.0%)
Gender (male)	610	18 (39.1%)	226 (40.1%)	244 (40.0%)
Preinjection IOP in study eye	607	16.8 (3.8)	15.3 (3.1)	15.4 (3.2)
Postinjection IOP change in study eye	594	2.8 (6.5)	3.1 (5.6)	3.1 (5.7)
Preinjection IOP eye difference (study eye IOP minus fellow eye IOP)	606	−0.7 (3.8)	0.0 (1.6)	−0.1 (1.9)
During the trial
Any cataract surgery (pseudo/aphakic)	610	27 (58.7%)	192 (34.0%)	219 (35.9%)
In study eye only		7 (25.9%)	39 (20.3%)	46 (21.0%)
In fellow eye only		3 (11.1%)	29 (15.1%)	32 (14.6%)
In both eyes		17 (63.0%)	124 (64.6%)	141 (64.4%)
Months in trial	610	23.5 (23.0 to 24.5)	23.6 (22.8 to 24.3)	23.6 (22.8 to 24.3)
Months between injections	13 371	1.0 (0.9 to 1.8)	1.0 (0.9 to 1.2)	1.0 (0.9 to 1.2)
Time (min) between injection and postinjection IOP measurement	9966	25 (15 to 33)	21 (12 to 32)	22 (13 to 32)
Mean arterial pressure (mm Hg)	4795	95.4 (10.6)	96.3 (10.9)	96.2 (10.9)
Preinjection IOP in study eye	13 281	16.6 (4.0)	15.3 (3.3)	15.4 (3.4)
Postinjection IOP change in study eye	10 009	4.4 (6.9)	3.8 (5.3)	3.8 (5.4)
Preinjection IOP eye difference (study eye IOP minus fellow eye IOP)	13, 208	−0.4 (5.0)	0.1 (1.8)	0.5 (2.3)
At visit 24
Preinjection IOP in study eye	514	17.0 (4.0)	15.7 (3.3)	15.8 (3.4)
Postinjection IOP change in study eye (at visit 23)	358	5.1 (4.1)	3.9 (5.1)	4.0 (5.0)
Preinjection IOP eye difference (study eye IOP minus fellow eye IOP)	510	0.5 (2.2)	0.2 (1.9)	0.2 (1.9)

IOP, intraocular pressure.